Now in its 4th year, AFDD is the industry’s definitive guide to turning fibrotic mechanisms into clinically effective therapeutics across disease areas. With 3 days of in-depth cutting-edge case studies and the highest calibre of academic discussions, AFDD will provide the roadmap to anti-fibrotic drug development success.
Hear from pioneering experts from Roche, Genentech, Merck, Harvard, Gilead & more as they guide you to overcome the hurdles currently in the way of developing truly clinically effective antifibrotics.
Built from extensive research with 25+ key stakeholders, this forum will explore only the hottest topics in the space including:
- Enhancing Understanding of Fibrotic Disease Cell Types & Pathogenesis to Inform the Next Generation of Druggable Targets
- Tackling Translation: Bridging the Translational Gap by Assessing Current & Future Model Systems
- Revealing Fibrotic Biomarkers & Endpoints in the Context of Ongoing Clinical Trials
Whilst we might not be able to meet physically, through this virtual platform we remain committed to meeting your needs for the latest antifibrotic drug development updates and meaningful connections so you don’t miss out on timely scientific insights, data and key lessons learned in 2020.
The next generation of antifibrotic treatments will be born at AFDD 2020.